EvolveImmune Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
23 Business Park Dr, Branford, Connectic...Phone Number
(203) 208-6584Website
www.evolveimmune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About EvolveImmune Therapeutics
EvolveImmune Therapeutics is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation, addressing the challenges of cancer cell resistance to current immunotherapies. The company's lead drug candidate, EVOLVE104, is set to enter clinical trials in 2025. EvolveImmune is committed to improving the lives of cancer patients and their families through innovative therapeutic solutions. They have also partnered with Abbvie to develop additional therapeutics leveraging the power of costimulation.Explore more
EvolveImmune Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EvolveImmune Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if EvolveImmune Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once EvolveImmune Therapeutics has new funding data
Check out if EvolveImmune Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when EvolveImmune Therapeutics launches new products
EvolveImmune Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if EvolveImmune Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on EvolveImmune Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at EvolveImmune Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to EvolveImmune Therapeutics
Compare insights from companies similar to EvolveImmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
EvolveImmune Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EvolveImmune Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EvolveImmune Therapeutics.
EvolveImmune Therapeutics financials insights
Gather financial insights about EvolveImmune Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$37M
EvolveImmune Therapeutics Tech Stack
A closer look at the technologies used by EvolveImmune Therapeutics
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Executive Move
Executive Moves, Board of Directors
EvolveImmune Therapeutics News & Media
EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting
Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanEvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting
Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104EvolveImmune Therapeutics Announces Initiation of Dosing in a Phase 1 Trial of EVOLVE104 in Patients with Solid Tumors
EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the ClinicEvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation
First Program from EVOLVE T-Cell Engager Platform to Advance into Clinical Development
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EvolveImmune Therapeutics
Sign Up For FreeTo access detailed company insights
EvolveImmune Therapeutics is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation, addressing the challenges of cancer cell resistance to current immunotherapies. The company's lead drug candidate, EVOLVE104, is set to enter clinical trials in 2025. EvolveImmune is committed to improving the lives of cancer... Read More
